Healthtech & Biotech - Research Innovation

Hero banner illustration for "Saccade builds VR eye test to detect Alzheimer's 15 years early"

Healthtech & BiotechOctober 7, 2026

Saccade builds VR eye test to detect Alzheimer's 15 years early

YC-backed startup uses eye-tracking biomarkers in 15-minute VR assessment, entering race against blood tests to catch disease before symptoms as new drugs demand earlier diagnosis

YcHealthtech+3

Hero banner illustration for "Autopoiesis Sciences raises $11M to build AI research partner"

Healthtech & BiotechOctober 6, 2026

Autopoiesis Sciences raises $11M to build AI research partner

Applied AI lab's 'Aristotle' tool claims thousands of users at Pfizer, FDA, Harvard. Threshold Ventures leads seed for autonomous scientific discovery platform.

AiDrug Discovery+3

Hero banner illustration for "Halmos Labs automates biotech R&D with AI-driven design"

Healthtech & BiotechOctober 3, 2026

Halmos Labs automates biotech R&D with AI-driven design

YC-backed startup tackles drug discovery bottleneck with AI that designs experiments for maximum information gain while validating its own assumptions.

YcDrug Discovery+3

Hero banner illustration for "Petrichor Bio launches AI wet lab platform for biology"

Healthtech & BiotechOctober 3, 2026

Petrichor Bio launches AI wet lab platform for biology

YC-backed startup by three 19-year-olds debuts autonomous wet lab infrastructure enabling AI agents to design, execute, and learn from real biology experiments.

YcBiotech+3

Hero banner illustration for "Aignosis raises ₹4 crore to scale AI autism screening"

Healthtech & BiotechOctober 2, 2026

Aignosis raises ₹4 crore to scale AI autism screening

Indian startup's webcam-based platform screens toddlers in 3 minutes, deployed across government health centers as specialized care shortages hit 96% of pediatricians.

AiPediatric Care+3

Hero banner illustration for "SuperRadiant builds robotic experimentalists for science"

Healthtech & BiotechOctober 1, 2026

SuperRadiant builds robotic experimentalists for science

YC-backed startup combines AI reasoning with physical robotics to autonomously design and run experiments, aiming to accelerate discovery in biotech and materials research.

YcRobotics+3

Hero banner illustration for "WonderTx builds AI to replace injectable drugs with pills"

Healthtech & BiotechSeptember 27, 2026

WonderTx builds AI to replace injectable drugs with pills

YC-backed startup from ex-Atomwise founder uses extrapolative AI to convert biologics like insulin and Ozempic into oral medications, targeting $200B validated market.

YcDrug Delivery+3

Hero banner illustration for "TareBio develops rapid vaccine platform for cancer, infections"

Healthtech & BiotechSeptember 23, 2026

TareBio develops rapid vaccine platform for cancer, infections

YC-backed biotech tackles personalized cancer vaccines and pandemic preparedness with platform that creates immunizations in weeks, joining race transformed by mRNA breakthroughs.

YcBiotech+3

Hero banner illustration for "Edgerun launches military exoskeleton with $100M+ in LOIs"

Healthtech & BiotechSeptember 14, 2026

Edgerun launches military exoskeleton with $100M+ in LOIs

YC-backed defense startup's powered hip exoskeleton completes 100+ field tests with Ukrainian forces, targeting logistics and combat applications with 12+ hour runtime.

YcDefense Tech+3

Hero banner illustration for "WonderTx uses extrapolative AI to turn injections into pills"

Healthtech & BiotechSeptember 12, 2026

WonderTx uses extrapolative AI to turn injections into pills

Atomwise co-founder's new startup uses AI that works without training data to discover oral versions of injectable biologics in the booming GLP-1 market

Drug DiscoveryDrug Delivery+3

Hero banner illustration for "Parasma trains human brain cells to predict AI tokens"

Healthtech & BiotechSeptember 8, 2026

Parasma trains human brain cells to predict AI tokens

YC-backed startup achieves 90% accuracy on next-token prediction using living neurons, claiming breakthrough that exceeds what linear silicon decoders can achieve.

YcOrganoid Computing+3

Hero banner illustration for "Frontier raises $10M to grow biological brains for AI training"

Healthtech & BiotechSeptember 1, 2026

Frontier raises $10M to grow biological brains for AI training

YC-backed startup claims breakthrough in scaling neural organoids from 1M to 100M+ neurons, positioning living tissue as energy-efficient alternative to silicon chips

YcBiotech+3

Hero banner illustration for "Gamgee raises $4M to scale AI-powered cancer vaccines for dogs"

Healthtech & BiotechAugust 28, 2026

Gamgee raises $4M to scale AI-powered cancer vaccines for dogs

The YC-backed startup uses genomics and AI to design personalized mRNA vaccines for canine cancer in 48 hours, potentially opening path to human treatments.

YcOncology+3

Hero banner illustration for "WonderTx builds AI to turn injectable drugs into pills"

Healthtech & BiotechAugust 14, 2026

WonderTx builds AI to turn injectable drugs into pills

YC-backed biotech aims to replace needles with pills for blockbuster drugs like Ozempic and insulin using AI-driven formulation technology in a $200B market.

YcBiotech+3

Hero banner illustration for "AI-native radiology practices rebuild care from scratch"

Healthtech & BiotechAugust 11, 2026

AI-native radiology practices rebuild care from scratch

New breed of radiology services built on AI foundation models and cloud platforms are proving the business case, with early adopters hitting $97M ARR and drafting reports in seconds.

Clinical AiDiagnostic Imaging+3

Hero banner illustration for "Neuromorphic launches plug-and-play robot brains for wet labs"

Healthtech & BiotechAugust 11, 2026

Neuromorphic launches plug-and-play robot brains for wet labs

YC S26 startup's embodiment-agnostic AI platform lets one 'brain' control different robot bodies through Slack and email, starting with 24/7 autonomous lab automation.

YcLab Automation+3

Hero banner illustration for "Living Neurons as AI Hardware: Inside the Biocomputing Revolution"

Healthtech & BiotechAugust 10, 2026

Living Neurons as AI Hardware: Inside the Biocomputing Revolution

From YC-backed Parasma to $25M-funded startups, companies are training human brain cells for computation—promising radical energy savings but raising new ethical questions.

YcAi Hardware+3

Hero banner illustration for "The Race to Develop Personalized Vaccines in Weeks, Not Months"

Healthtech & BiotechAugust 9, 2026

The Race to Develop Personalized Vaccines in Weeks, Not Months

How biotech startups and pharma giants are using AI and immune profiling to slash vaccine development timelines from months to weeks—transforming cancer treatment and pandemic response.

Precision MedicineImmunotherapy+3

Hero banner illustration for "The AI Race to Predict Clinical Trial Outcomes Before They Fail"

Healthtech & BiotechAugust 9, 2026

The AI Race to Predict Clinical Trial Outcomes Before They Fail

Foundation models and digital twins promise to cut drug development costs by billions. Atlas Discovery and others are making regulatory-backed predictions a reality in 2026.

Clinical TrialsDrug Development+3

Hero banner illustration for "Wetware Computing: How Startups Are Training Brain Cells for AI"

Healthtech & BiotechAugust 8, 2026

Wetware Computing: How Startups Are Training Brain Cells for AI

As data centers face a $7T buildout and soaring energy costs, a wave of biocomputing startups—from YC-backed Parasma to Cortical Labs—are racing to turn living neurons into AI processors.

Wetware ComputingYc+3

Hero banner illustration for "The Race to Build Computers from Human Brain Cells"

Healthtech & BiotechAugust 7, 2026

The Race to Build Computers from Human Brain Cells

YC-backed Parasma joins field training living neurons for AI compute. As data centers strain power grids, organoid intelligence emerges with promise—and profound ethical questions.

YcWetware Computing+3

Hero banner illustration for "Brain Cells as Processors: Inside Parasma's Biocomputing Breakthrough"

Healthtech & BiotechAugust 5, 2026

Brain Cells as Processors: Inside Parasma's Biocomputing Breakthrough

YC-backed Parasma trains living human neurons for AI tasks, joining a wave of startups racing to build biological alternatives to power-hungry GPUs amid an AI energy crisis.

YcWetware Computing+3

Hero banner illustration for "The Race to Build Personalized Vaccines in Weeks, Not Months"

Healthtech & BiotechAugust 4, 2026

The Race to Build Personalized Vaccines in Weeks, Not Months

How a new wave of biotech startups is using 'immune imprinting' to create custom cancer and infectious disease vaccines faster than ever—challenging giants like Moderna.

BiotechOncology+3

Hero banner illustration for "Living Computers: Inside the Race to Train Brain Cells for AI"

Healthtech & BiotechAugust 3, 2026

Living Computers: Inside the Race to Train Brain Cells for AI

As AI power demand soars, startups like YC-backed Parasma are building the next compute frontier: wetware systems that train human neurons to process information at a fraction of silicon's energy cost.

Wetware ComputingAi Hardware+3

Hero banner illustration for "MOYA Robot and China's Emotional AI Push Face Verification Hurdles"

Healthtech & BiotechAugust 3, 2026

MOYA Robot and China's Emotional AI Push Face Verification Hurdles

DroidUp's humanoid claims 92% human gait accuracy and warm skin, but as eldercare robots advance, regulatory barriers and unverified metrics reveal gaps between promise and proof.

Humanoid RoboticsSenior Care+2

Hero banner illustration for "From Lab Meat to Lipstick: IntegriCulture's Profitable Pivot"

Healthtech & BiotechAugust 3, 2026

From Lab Meat to Lipstick: IntegriCulture's Profitable Pivot

Facing regulatory delays, Japanese biotech IntegriCulture turned cell-culture tech into cosmetic ingredients—and hit profitability in 2025 with $255K net profit.

BiotechBeauty Tech+3

Hero banner illustration for "How TareBio Aims to Build Personalized Cancer Vaccines in Weeks"

Healthtech & BiotechAugust 2, 2026

How TareBio Aims to Build Personalized Cancer Vaccines in Weeks

YC S26 biotech startup's 'immune imprint' method bypasses traditional antigen prediction, entering a race where Moderna and BioNTech lead with 4-7 week timelines.

YcOncology+3

Hero banner illustration for "Brain Cells as AI Chips: The Race to Build Biological Computers"

Healthtech & BiotechAugust 2, 2026

Brain Cells as AI Chips: The Race to Build Biological Computers

As AI energy costs soar, startups like YC's Parasma are training human neurons to compute—promising million-fold efficiency gains while raising profound ethical questions.

YcWetware Computing+3

Hero banner illustration for "How AI Radiology Startups Are Bridging India's Healthcare Gap"

Healthtech & BiotechAugust 1, 2026

How AI Radiology Startups Are Bridging India's Healthcare Gap

With just 1.9 radiologists per 100,000 people, India's startups are deploying AI screening at massive scale—100,000+ scans in pilot programs—proving cost-effective solutions work.

Clinical AiDiagnostic Imaging+2

Hero banner illustration for "Atlas Discovery Uses AI to Predict Drug Trial Outcomes"

Healthtech & BiotechJuly 30, 2026

Atlas Discovery Uses AI to Predict Drug Trial Outcomes

YC-backed startup's foundation models claim 70-90% accuracy in forecasting patient response, targeting pharma's $244M Phase III failure problem.

YcClinical Ai+3

Hero banner illustration for "The Probiotic Startup Where Customers Pay to Generate AI Training Data"

Healthtech & BiotechJuly 28, 2026

The Probiotic Startup Where Customers Pay to Generate AI Training Data

GutGutGoose inverts the TechBio playbook: sell personalized probiotics, use follow-up microbiome tests as labeled datasets. Can a consumer product finance the next frontier in AI?

BiotechTraining Data+3

Hero banner illustration for "Living Compute: Startups Train Human Brain Cells to Run AI"

Healthtech & BiotechJuly 24, 2026

Living Compute: Startups Train Human Brain Cells to Run AI

As data centers face energy crises, biotech startups like Parasma use cultured neurons for AI tasks—teaching brain cells to play Doom and opening a new frontier in biological computing.

BiotechAi Hardware+3

Hero banner illustration for "Cheiron's $8M Seed Signals Race to Build Operating Systems for Drug R&D"

Healthtech & BiotechJuly 23, 2026

Cheiron's $8M Seed Signals Race to Build Operating Systems for Drug R&D

As pharma giants like BMS and GSK build internal AI platforms, Cheiron's early Korean traction reveals a market for unified drug development infrastructure—and a bet that knowledge graphs beat chatbots.

Drug DevelopmentKnowledge Graphs+3

Hero banner illustration for "Brain Cells as Computers: Inside the Biotech Race to Power AI"

Healthtech & BiotechJuly 22, 2026

Brain Cells as Computers: Inside the Biotech Race to Power AI

As AI's energy crisis deepens, startups like YC-backed Parasma are training living neurons to compute. Melbourne just launched the world's first biological data center. The future of AI may be alive.

YcWetware Computing+3

Hero banner illustration for "AI Predicting Drug Response: The Race to Fix Clinical Trials"

Healthtech & BiotechJuly 22, 2026

AI Predicting Drug Response: The Race to Fix Clinical Trials

From digital twins to foundation models, AI systems are finally cracking human drug response prediction—with FDA backing, pharma adoption, and fresh breakthroughs in 2026.

Clinical TrialsDrug Discovery+3

Hero banner illustration for "AI Models Predict Drug Response, Promising Faster Clinical Trials"

Healthtech & BiotechJuly 21, 2026

AI Models Predict Drug Response, Promising Faster Clinical Trials

With drug development costs hitting $2.67B per therapy, AI startups like YC's Atlas Discovery are building models to predict patient response—cutting trial sizes and failure rates.

YcClinical Ai+3

Hero banner illustration for "Living Computers: Inside Parasma's Quest to Turn Brain Cells Into AI"

Healthtech & BiotechJuly 18, 2026

Living Computers: Inside Parasma's Quest to Turn Brain Cells Into AI

YC-backed Parasma is training human neurons to perform AI tasks, promising radical energy savings. But can biological computing scale—and what are the ethical costs?

YcWetware Computing+3

Hero banner illustration for "AI Models Now Predict Drug Trials—Could Save Billions"

Healthtech & BiotechJuly 18, 2026

AI Models Now Predict Drug Trials—Could Save Billions

Atlas Discovery and others are building AI to predict which patients will respond to drugs—potentially cutting trial costs by 70% and rescuing failed compounds.

Clinical AiDrug Discovery+2

Hero banner illustration for "Training Brain Cells to Compute: Inside the Biological AI Revolution"

Healthtech & BiotechJuly 17, 2026

Training Brain Cells to Compute: Inside the Biological AI Revolution

As AI energy costs spiral, YC-backed Parasma and pioneers like Cortical Labs are building algorithms that train living human neurons to perform computation—opening a frontier in wetware computing.

YcBiotech+3

Hero banner illustration for "OpenAI Researcher Miles Wang Raises $200M for AI Drug Startup at $2B Valuation"

Healthtech & BiotechJuly 16, 2026

OpenAI Researcher Miles Wang Raises $200M for AI Drug Startup at $2B Valuation

Former OpenAI safety researcher Miles Wang is reportedly raising $200M at a ~$2B valuation for a new AI drug-discovery venture, joining a red-hot sector that's attracted $6B+ in 2026 alone.

Drug DiscoveryAi+3

Hero banner illustration for "Living Neurons as Compute: Inside the Race to Build Biological AI"

Healthtech & BiotechJuly 15, 2026

Living Neurons as Compute: Inside the Race to Build Biological AI

YC-backed Parasma and rivals are training human brain cells to perform AI tasks, racing to commercialize wetware computing as data center power demands soar. Can biology outpace silicon?

YcBiotech+3

Hero banner illustration for "Brain Cells as Compute: The Biotech Startups Racing to Solve AI's Energy Crisis"

Healthtech & BiotechJuly 13, 2026

Brain Cells as Compute: The Biotech Startups Racing to Solve AI's Energy Crisis

As data centers consume 1,000+ TWh annually, companies like YC-backed Parasma are training human neurons as living processors—achieving breakthroughs that could reshape computing.

YcBiotech+3

Hero banner illustration for "Living Neurons as AI Chips: The Race to Build Biological Computers"

Healthtech & BiotechJuly 11, 2026

Living Neurons as AI Chips: The Race to Build Biological Computers

As data centers consume 6% of US electricity, startups like YC-backed Parasma are training human brain cells to perform AI tasks—using a million times less power than silicon.

YcAi Hardware+3

Hero banner illustration for "Living Neurons Meet AI: Inside the Race to Build Biological Computers"

Healthtech & BiotechJuly 10, 2026

Living Neurons Meet AI: Inside the Race to Build Biological Computers

Brain organoids are learning to play games and power data centers. As AI energy costs soar, startups like YC-backed Parasma are turning human neurons into programmable compute infrastructure.

YcBiotech+3

Hero banner illustration for "How Direct tRNA Charging Measurement Could Fix Biotech's Yield Problem"

Healthtech & BiotechJuly 10, 2026

How Direct tRNA Charging Measurement Could Fix Biotech's Yield Problem

University of Colorado nanopore breakthrough enables real-time visibility into protein production bottlenecks. Startup Andon Bio is commercializing the tech for biopharma manufacturing.

BiotechDrug Manufacturing+2

Hero banner illustration for "Brain Cells as AI Compute: Inside the Biocomputing Revolution"

Healthtech & BiotechJuly 8, 2026

Brain Cells as AI Compute: Inside the Biocomputing Revolution

As data centers threaten to double energy use by 2030, startups like YC-backed Parasma are training living neurons to replace silicon—opening a new frontier in sustainable AI.

YcBiotech+3

Hero banner illustration for "Space Becomes the New Drug Lab: Microgravity Testing Goes Commercial"

Healthtech & BiotechJuly 8, 2026

Space Becomes the New Drug Lab: Microgravity Testing Goes Commercial

As pharma giants partner with orbital platforms, microgravity drug discovery shifts from NASA demos to standardized services—with billions in market potential by 2030.

Space TechDrug Discovery+2

Hero banner illustration for "Living Neurons as AI Chips: YC's Bet on Biological Computing"

Healthtech & BiotechJuly 7, 2026

Living Neurons as AI Chips: YC's Bet on Biological Computing

As data centers face energy crisis, YC-backed Parasma trains human brain cells for compute. Founder who made neurons play DOOM now tackles AI's power problem.

YcBiotech+3

Hero banner illustration for "The Race to Build Virtual Cells: AI Models That Predict Drug Response"

Healthtech & BiotechJuly 7, 2026

The Race to Build Virtual Cells: AI Models That Predict Drug Response

Startups and pharma giants are competing to create digital twins of human cells that could transform drug discovery—cutting trial costs and accelerating cures.

Drug DiscoveryDigital Twins+3

Hero banner illustration for "Virtual Cells: How AI Models Are Reinventing Drug Discovery in 2026"

Healthtech & BiotechJuly 5, 2026

Virtual Cells: How AI Models Are Reinventing Drug Discovery in 2026

Atlas Discovery and a wave of biotech startups are using foundation models to simulate cellular biology—cutting trial costs, rescuing failed drugs, and accelerating disease understanding.

Drug DiscoveryAi+3

Hero banner illustration for "The Virtual Cell Revolution: Mapping Disease Biology With AI"

Healthtech & BiotechJuly 3, 2026

The Virtual Cell Revolution: Mapping Disease Biology With AI

A new wave of biotech startups like Atlas Discovery are using AI-powered 'virtual cells' to predict drug response and shrink clinical trials—a shift that could reshape pharma R&D.

AiDrug Discovery+3

Hero banner illustration for "India's First Helium-Free MRI: Can Voxelgrids Crack the Access Gap?"

Healthtech & BiotechJuly 1, 2026

India's First Helium-Free MRI: Can Voxelgrids Crack the Access Gap?

Bengaluru startup's indigenous 1.5T scanner tackles helium scarcity as global MRI giants pivot to sealed magnets. Inside the tech, market forces, and race to democratize imaging.

Diagnostic ImagingMedical Devices+2

Hero banner illustration for "Living Neurons Are Learning to Compute: Inside Biological AI's Race"

Healthtech & BiotechJuly 1, 2026

Living Neurons Are Learning to Compute: Inside Biological AI's Race

YC-backed Parasma and rivals are training human brain cells to run AI tasks, promising massive energy savings. But can wetware computing scale beyond lab demos?

YcBiotech+3

Hero banner illustration for "DNA-Triggered Drugs: Inside the Race to Cure 'Undruggable' Diseases"

Healthtech & BiotechJune 29, 2026

DNA-Triggered Drugs: Inside the Race to Cure 'Undruggable' Diseases

YC-backed FinalDose and a wave of programmable therapeutics aim to unlock 80% of diseases resistant to traditional drugs. Can DNA-recognition technology deliver on its promise?

YcDrug Discovery+3

Hero banner illustration for "From Words to Workflows: AI's Push to Automate Lab Instruments"

Healthtech & BiotechJune 27, 2026

From Words to Workflows: AI's Push to Automate Lab Instruments

Natural language interfaces are transforming lab automation, promising to replace vendor-specific scripting with plain English. But can AI deliver validated, compliance-ready protocols?

Lab AutomationAi Automation+3

Hero banner illustration for "The Race to Reinvent MRI: How Startups Are Making Cancer Screening Affordable"

Healthtech & BiotechJune 27, 2026

The Race to Reinvent MRI: How Startups Are Making Cancer Screening Affordable

From helium-free magnets to AI-powered scans, a new wave of portable MRI technology is challenging the $7B imaging market—and Adialante's RF-encoded system is leading the charge.

Portable MriDiagnostic Imaging+3

Hero banner illustration for "YC-Backed Twolabs Launches Robot Platform to Democratize Caregiving AI"

Healthtech & BiotechJune 27, 2026

YC-Backed Twolabs Launches Robot Platform to Democratize Caregiving AI

Startup's modular humanoid and 'no-code' training software targets nursing homes as $38B robotics market heats up with Agility's SPAC and Amazon's Fauna acquisition.

YcHumanoid Robotics+3

Hero banner illustration for "The Race to Program DNA Drugs: Can Biotech Unlock Cancer's 80%?"

Healthtech & BiotechJune 27, 2026

The Race to Program DNA Drugs: Can Biotech Unlock Cancer's 80%?

FinalDose and others pursue 'programmable' DNA therapeutics targeting previously undruggable cancer genes. Early promise meets scientific scrutiny in nascent field.

OncologyGene Therapy+2

Hero banner illustration for "Space Manufacturing's Bottleneck: The Race to Bring Products Home"

Healthtech & BiotechJune 26, 2026

Space Manufacturing's Bottleneck: The Race to Bring Products Home

As microgravity factories come online, return logistics—not launch costs—now limit space-based drug and semiconductor production. New reentry vehicles aim to unlock the market.

Space TechDrug Manufacturing+3

Hero banner illustration for "The Race to Build Reusable Space Factories: How Reentry Vehicles Are Unlocking Orbital Drug Manufacturing"

Healthtech & BiotechJune 21, 2026

The Race to Build Reusable Space Factories: How Reentry Vehicles Are Unlocking Orbital Drug Manufacturing

As companies like Varda and Space Forge prove microgravity manufacturing works, a new wave of refurbishable reentry vehicles aims to solve the logistics bottleneck threatening the $1.8T space economy.

Space TechDrug Manufacturing+3

Hero banner illustration for "Foundation Models Come to Drug Manufacturing: AbInitio Bio's Echo"

Healthtech & BiotechJune 17, 2026

Foundation Models Come to Drug Manufacturing: AbInitio Bio's Echo

YC-backed AbInitio Bio applies foundation models to biomanufacturing, claiming its Echo model can reduce six-month manufacturing decisions to hours—validated with wet lab data.

YcBiotech+3

Hero banner illustration for "Gradient-Free MRI: How Adialante Plans to Democratize Cancer Screening"

Healthtech & BiotechJune 17, 2026

Gradient-Free MRI: How Adialante Plans to Democratize Cancer Screening

YC-backed startup uses novel RF-encoding to build portable, low-cost MRI systems. Could $1.18M NSF grant and mobile clinics make diagnostic imaging accessible to millions?

YcPortable Mri+3

Hero banner illustration for "Space Manufacturing's Missing Link: The Race for Reusable Return Vehicles"

Healthtech & BiotechJune 15, 2026

Space Manufacturing's Missing Link: The Race for Reusable Return Vehicles

As companies prove they can make semiconductors and drugs in orbit, startups like Dispatch, Varda, and Space Forge are racing to solve the return trip with refurbishable reentry tech.

Space TechAerospace+3

Hero banner illustration for "Mobile MRI Startup Aims to Democratize Early Cancer Screening"

Healthtech & BiotechJune 13, 2026

Mobile MRI Startup Aims to Democratize Early Cancer Screening

Adialante's gradientless MRI technology promises to bring affordable diagnostic imaging to clinic parking lots, starting with prostate cancer screening at urology practices.

Diagnostic ImagingPortable Mri+3

Hero banner illustration for "The Rise of Socially Intelligent Robots in Elder Care Facilities"

Healthtech & BiotechJune 12, 2026

The Rise of Socially Intelligent Robots in Elder Care Facilities

As staffing shortages intensify and 61M Americans turn 65+, startups like YC-backed Twolabs are deploying AI-powered humanoids to assist with caregiving tasks in nursing homes.

YcHumanoid Robotics+3

Hero banner illustration for "FinalDose's DNA-Targeting Drug Aims to Unlock 'Undruggable' Cancers"

Healthtech & BiotechJune 12, 2026

FinalDose's DNA-Targeting Drug Aims to Unlock 'Undruggable' Cancers

YC-backed biotech unveils programmable molecule that recognizes cancer-causing DNA sequences and triggers cell death—potentially addressing 80% of targets beyond conventional drugs' reach.

YcOncology+3

Hero banner illustration for "How Adialante Plans to Bring MRI Screening to Every Clinic"

Healthtech & BiotechJune 11, 2026

How Adialante Plans to Bring MRI Screening to Every Clinic

Y Combinator-backed startup uses patented RF encoding to shrink MRI scanners by 80%, targeting early cancer detection as helium crisis squeezes traditional systems.

YcPortable Mri+3

Hero banner illustration for "Programmable DNA Drugs: The Race to Target 'Undruggable' Cancers"

Healthtech & BiotechJune 3, 2026

Programmable DNA Drugs: The Race to Target 'Undruggable' Cancers

A new wave of biotech startups is betting on DNA-reading therapeutics to unlock the 80% of cancer targets current drugs can't reach. Inside the science rewriting oncology's rulebook.

OncologyDrug Discovery+2

Hero banner illustration for "YC-Backed Lumius Aims to Democratize 3D Ultrasound for Procedures"

Healthtech & BiotechJune 2, 2026

YC-Backed Lumius Aims to Democratize 3D Ultrasound for Procedures

Durham-based startup leverages novel diffractive acoustic tomography to bring affordable, real-time 3D ultrasound to vascular access—addressing a major training bottleneck.

YcMedical Devices+2

Hero banner illustration for "How AI Agents Are Automating Biopharma's Multi-Billion R&D Crisis"

Healthtech & BiotechJune 2, 2026

How AI Agents Are Automating Biopharma's Multi-Billion R&D Crisis

As pharma giants rush to deploy agentic AI across drug development, a wave of startups promise to compress years-long pipelines—but regulatory scrutiny and validation gaps loom large.

Ai AgentsDrug Discovery+3

Hero banner illustration for "AI-Native CROs Take On Clinical Trials' Efficiency Crisis"

Healthtech & BiotechJune 1, 2026

AI-Native CROs Take On Clinical Trials' Efficiency Crisis

Harbor's evolution from EDC to full-service CRO in months signals a broader shift: AI-first platforms compressing trial timelines from 12 weeks to 9 days.

Clinical TrialsClinical Ai+3

Hero banner illustration for "The Battle to Control Lab Instruments with Natural Language"

Healthtech & BiotechMay 29, 2026

The Battle to Control Lab Instruments with Natural Language

YC-backed Infera joins Benchling, Ginkgo, and Opentrons in a 2026 race to replace vendor scripts with plain English—a shift that could unlock autonomous laboratory workflows.

YcLab Automation+3

Hero banner illustration for "Can DNA-Targeting Drugs Crack 80% of 'Undruggable' Cancers?"

Healthtech & BiotechMay 28, 2026

Can DNA-Targeting Drugs Crack 80% of 'Undruggable' Cancers?

YC-backed FinalDose claims breakthrough programmable DNA drug platform targets previously unreachable cancer markers. Industry analysis reveals hype, promise, and hurdles.

YcOncology+3

Hero banner illustration for "How Adialante's Mobile MRI Aims to Crack the Cancer Screening Gap"

Healthtech & BiotechMay 23, 2026

How Adialante's Mobile MRI Aims to Crack the Cancer Screening Gap

A YC Spring 2026 startup is developing mobile, diagnostic-quality MRI technology to democratize early cancer screening—starting with prostate imaging at a fraction of traditional costs.

YcPortable Mri+3

Hero banner illustration for "The $12B Race to Build Factories in Space—and Bring the Goods Home"

Healthtech & BiotechMay 23, 2026

The $12B Race to Build Factories in Space—and Bring the Goods Home

As the ISS nears retirement, a new generation of startups is building reentry vehicles to shuttle high-value drugs, semiconductors, and biotech materials from orbit to Earth.

Space TechBiotech+3

Hero banner illustration for "How Adialante Made MRI 80% Lighter for Early Cancer Detection"

Healthtech & BiotechMay 20, 2026

How Adialante Made MRI 80% Lighter for Early Cancer Detection

YC S26's Adialante uses RF-encoding physics to reimagine MRI from the ground up—delivering diagnostic-grade scans in a mobile system that eliminates barriers to early screening.

YcPortable Mri+3

Hero banner illustration for "BioOrbit Launches Protein Drug Factory to Space Station"

Healthtech & BiotechMay 19, 2026

BioOrbit Launches Protein Drug Factory to Space Station

UK startup's Baby BOX-E crystallizer reaches ISS after record $13M seed round, marking shift from space experiments to orbital pharmaceutical manufacturing at scale.

Space TechBiotech+3

Hero banner illustration for "The Race to Build Programmable DNA Drugs That Target Any Cancer"

Healthtech & BiotechMay 13, 2026

The Race to Build Programmable DNA Drugs That Target Any Cancer

A wave of startups and academic labs are developing 'programmable' therapeutics that can be reprogrammed to target different genetic sequences—potentially unlocking 85% of disease pathways.

OncologyDrug Development+3

Hero banner illustration for "Y Combinator Biotech Targets 'Undruggable' Cancers With Programmable DNA"

Healthtech & BiotechMay 12, 2026

Y Combinator Biotech Targets 'Undruggable' Cancers With Programmable DNA

Oxford-founded FinalDose joins wave of logic-gated therapeutics tackling the 80% of disease proteins conventional drugs can't reach—but faces steep validation hurdles.

YcBiotech+3

Hero banner illustration for "Dispatch Space Builds Low-Cost Reentry Vehicles for Orbital Factories"

Healthtech & BiotechMay 9, 2026

Dispatch Space Builds Low-Cost Reentry Vehicles for Orbital Factories

YC-backed startup targets 100x cheaper heat shields to enable pharmaceutical and semiconductor manufacturing in microgravity, with first demo flight planned for mid-2027.

YcSpace Tech+3

Hero banner illustration for "UK Launches £150K Venture Builder for Deep-Tech Spin-Outs"

Healthtech & BiotechMay 7, 2026

UK Launches £150K Venture Builder for Deep-Tech Spin-Outs

Innovate UK's £3.75m pilot targets university spin-outs in Frontier AI, Engineering Biology, and Advanced Materials—bridging the gap from research to investment.

DeeptechUk Tech+3

Hero banner illustration for "The Race to Build Factories in Space for Pharma and Semiconductors"

Healthtech & BiotechMay 6, 2026

The Race to Build Factories in Space for Pharma and Semiconductors

As demand grows for materials that can only be made in microgravity, startups are racing to build reentry vehicles and orbital platforms for manufacturing drugs and chips in space.

Space TechAerospace+3

Hero banner illustration for "How AI Is Slashing Biotech Image Analysis Time by 98%"

Healthtech & BiotechMay 5, 2026

How AI Is Slashing Biotech Image Analysis Time by 98%

YC-backed Alchemy joins a wave of AI tools transforming microscopy workflows as the computational pathology market races toward $1B. What it means for drug discovery timelines.

YcBiotech+3

Hero banner illustration for "The Race to Reinvent MRI: How Affordable Scanning Could Save Lives"

Healthtech & BiotechMay 5, 2026

The Race to Reinvent MRI: How Affordable Scanning Could Save Lives

Adialante and rivals are slashing MRI costs with mobile clinics and novel tech. Can sub-$500 scans unlock early cancer detection for millions—or will evidence gaps stall the movement?

Diagnostic ImagingMedical Devices+3

Hero banner illustration for "OPTISOLV's Dual-Coating Tech Promises 1,000x Boost in Supplement Absorption"

Healthtech & BiotechApril 16, 2026

OPTISOLV's Dual-Coating Tech Promises 1,000x Boost in Supplement Absorption

EVANIUM's cyclodextrin-phospholipid platform tackles nutraceutical bioavailability with clean-label delivery. Fresh off €2.2M seed, the tech is reshaping supplement efficacy.

NutraceuticalsBiotech+2

Hero banner illustration for "Finally Foods Raises $2.6M to Farm Dairy Proteins in Potatoes"

Healthtech & BiotechApril 12, 2026

Finally Foods Raises $2.6M to Farm Dairy Proteins in Potatoes

Israeli biotech Finally Foods is engineering potatoes to express dairy casein, positioning molecular farming as a scalable alternative to precision fermentation.

Alt ProteinBiotech+3

Hero banner illustration for "Climate-Health Tech Unlocks $300M+ in Equity-Free Funding"

Healthtech & BiotechApril 4, 2026

Climate-Health Tech Unlocks $300M+ in Equity-Free Funding

As traditional health aid declines, digital health startups tackling climate impacts are securing non-dilutive grants from UNICEF, WHO, ARPA-H, and philanthropies.

HealthtechClimate Tech+2

Hero banner illustration for "How 2 Employees Built a $401M Telehealth Startup Using AI"

Healthtech & BiotechApril 3, 2026

How 2 Employees Built a $401M Telehealth Startup Using AI

MEDVi scaled to $401M in revenue with just two employees by leveraging AI tools and outsourced infrastructure—but faces FDA scrutiny over its GLP-1 marketing practices.

TelehealthAi+3

Hero banner illustration for "How AI Is Redesigning DNA to Make Gene Therapy Safer"

Healthtech & BiotechMarch 31, 2026

How AI Is Redesigning DNA to Make Gene Therapy Safer

After fatal AAV therapy incidents, startups like Origin Bio are using machine learning to engineer precise genetic switches—potentially solving the field's biggest safety challenge.

Gene TherapyAi+3

Hero banner illustration for "AI Co-Scientists Take the Lab: How Automation Is Remaking R&D"

Healthtech & BiotechMarch 27, 2026

AI Co-Scientists Take the Lab: How Automation Is Remaking R&D

Synthetic Sciences and rivals are racing to build AI agents that run experiments end-to-end. With OpenAI, NVIDIA, and the DOE piling in, autonomous research is no longer science fiction.

Ai AgentsLab Automation+3

Hero banner illustration for "YC-Backed 10x Science Launches AI Platform to Solve Drug Dev Bottleneck"

Healthtech & BiotechMarch 27, 2026

YC-Backed 10x Science Launches AI Platform to Solve Drug Dev Bottleneck

Stanford-founded startup promises to shrink protein characterization from weeks to minutes, addressing critical gap as AI-powered drug discovery accelerates.

YcDrug Development+3

Hero banner illustration for "The Race to Build Infrastructure for Human Digital Twins in Healthcare"

Healthtech & BiotechMarch 27, 2026

The Race to Build Infrastructure for Human Digital Twins in Healthcare

As regulatory frameworks solidify and clinical trials embrace AI-powered simulations, startups are racing to build the foundational data layer for predictive human models.

Digital TwinsAi Infrastructure+3

Hero banner illustration for "Inside the Race to Build Digital Twins of Human Bodies"

Healthtech & BiotechMarch 26, 2026

Inside the Race to Build Digital Twins of Human Bodies

From clinical trials to surgical planning, healthcare's data fragmentation problem is blocking the path to personalized medicine. A new wave of startups is building the infrastructure.

Digital TwinsPrecision Medicine+3

Hero banner illustration for "AI Models Predict Missing Biology Data to Speed Drug Discovery"

Healthtech & BiotechMarch 25, 2026

AI Models Predict Missing Biology Data to Speed Drug Discovery

Strand AI's foundation models transform incomplete patient profiles into complete datasets, addressing a critical bottleneck in biotech research and clinical trials.

Drug DiscoveryAi+3

Hero banner illustration for "Mining Parasites for Cures: The New Frontier in Autoimmune Therapy"

Healthtech & BiotechMarch 24, 2026

Mining Parasites for Cures: The New Frontier in Autoimmune Therapy

YC-backed Ditto Biosciences and a wave of biotech startups are reverse-engineering parasites' immune-evasion tricks to develop breakthrough treatments for autoimmune diseases.

YcAutoimmune Disease+3

Hero banner illustration for "Brain's Drainage System: The Bioelectronic Bet Against Alzheimer's"

Healthtech & BiotechMarch 24, 2026

Brain's Drainage System: The Bioelectronic Bet Against Alzheimer's

As anti-amyloid drugs reach market, a wave of startups is targeting the brain's waste-clearance pathways with wearables and neuromodulation—redefining the fight against neurodegeneration.

NeurodegenerationNeurotechnology+2

Hero banner illustration for "Mining Parasite Evolution for Autoimmune Disease Therapies"

Healthtech & BiotechMarch 23, 2026

Mining Parasite Evolution for Autoimmune Disease Therapies

Ditto Biosciences uses AI to discover drugs from parasite proteins evolved to modulate human immunity, joining a $40B+ race to 'reset' rather than suppress autoimmune diseases.

Autoimmune DiseaseDrug Discovery+2

Hero banner illustration for "AI Co-Scientists: How Automation Is Reshaping Scientific Research"

Healthtech & BiotechMarch 23, 2026

AI Co-Scientists: How Automation Is Reshaping Scientific Research

From YC-backed startups to Google's lab validations, AI agents are moving from literature review to end-to-end experiment automation—transforming R&D economics.

YcAi Agents+3

Hero banner illustration for "AI Shifted Drug Development's Bottleneck—This Startup Wants to Fix It"

Healthtech & BiotechMarch 23, 2026

AI Shifted Drug Development's Bottleneck—This Startup Wants to Fix It

10x Science's AI platform automates protein characterization in minutes, tackling biotech's newest constraint as AlphaFold floods pipelines with candidates.

Drug DevelopmentProtein Characterization+3

Hero banner illustration for "Origin Bio's AI Challenges DeepMind in Gene Therapy Design"

Healthtech & BiotechMarch 23, 2026

Origin Bio's AI Challenges DeepMind in Gene Therapy Design

YC-backed startup releases AI platform outperforming DeepMind's AlphaGenome at designing regulatory DNA for safer cell therapies, plus 10,000 public sequences for cancer and CNS.

YcGene Therapy+3

Hero banner illustration for "AI Platform Tackles Drug Development's Protein Characterization Bottleneck"

Healthtech & BiotechMarch 22, 2026

AI Platform Tackles Drug Development's Protein Characterization Bottleneck

YC-backed 10x Science launches AI-native platform to accelerate biopharmaceutical development, compressing weeks of protein analysis into minutes as industry faces growing gap.

YcDrug Development+3

Hero banner illustration for "Digital Twins Transform Healthcare: The $9B Race to Model Humans"

Healthtech & BiotechMarch 21, 2026

Digital Twins Transform Healthcare: The $9B Race to Model Humans

As regulators greenlight computational models and data APIs mature, virtual twins are moving from research labs to clinical workflows—backed by new rules and billions in investment.

Digital TwinsHealthtech+3

Hero banner illustration for "Digital Twins of Human Biology Are Replacing Clinical Trials"

Healthtech & BiotechMarch 17, 2026

Digital Twins of Human Biology Are Replacing Clinical Trials

Regulatory breakthroughs and AI advances are turning computational models of human physiology into accepted evidence for drug approvals, reshaping a $70B+ market.

Digital TwinsClinical Trials+3

Hero banner illustration for "AI Co-Scientists Are Automating Research End-to-End. Can They Be Trusted?"

Healthtech & BiotechMarch 16, 2026

AI Co-Scientists Are Automating Research End-to-End. Can They Be Trusted?

As startups like Synthetic Sciences build platforms to automate the full scientific loop—from literature review to lab experiments—researchers adopt AI tools rapidly while regulators scramble to set guardrails.

Research AutomationAi Agents+3

Hero banner illustration for "Strand AI Predicts Missing Biology Data With Foundation Models"

Healthtech & BiotechMarch 16, 2026

Strand AI Predicts Missing Biology Data With Foundation Models

YC W26 startup launches POSTMAN to predict spatial proteomics from routine pathology slides, aiming to complete incomplete clinical trial datasets and reduce costly assay expenses.

YcSpatial Proteomics+3

Hero banner illustration for "AI Drug Discovery's Next Bottleneck: Protein Characterization"

Healthtech & BiotechMarch 15, 2026

AI Drug Discovery's Next Bottleneck: Protein Characterization

As AI floods biopharma pipelines with candidates, a YC W26 startup tackles the analytics crunch. Inside the $65B proteomics market's automation race.

Protein CharacterizationDrug Discovery+3

Hero banner illustration for "Mining Parasites for Drugs: Ditto Bio's Evolutionary Autoimmune Play"

Healthtech & BiotechMarch 15, 2026

Mining Parasites for Drugs: Ditto Bio's Evolutionary Autoimmune Play

YC-backed biotech harnesses millions of years of parasite evolution and AI to discover immunomodulators, as autoimmune therapeutics race toward curative approaches.

YcBiotech+3

Hero banner illustration for "Mining Parasite Evolution: Ditto Bio's Novel Path to Autoimmune Drugs"

Healthtech & BiotechMarch 14, 2026

Mining Parasite Evolution: Ditto Bio's Novel Path to Autoimmune Drugs

YC-backed startup maps viral, tick, and helminth proteins to human immune targets, betting millions of years of parasite evolution can unlock novel autoimmune therapies.

YcAutoimmune Disease+3

Hero banner illustration for "Strand AI Launches Models to Predict Missing Biology Data for Drug Trials"

Healthtech & BiotechMarch 14, 2026

Strand AI Launches Models to Predict Missing Biology Data for Drug Trials

YC W26 startup's POSTMAN predicts spatial proteomics from standard slides, aiming to rescue incomplete patient cohorts and accelerate pharma R&D timelines.

YcBiotech+3

Hero banner illustration for "AI-Designed DNA Sequences Tackle Gene Therapy Safety Crisis"

Healthtech & BiotechMarch 14, 2026

AI-Designed DNA Sequences Tackle Gene Therapy Safety Crisis

As FDA tightens AAV gene therapy oversight amid fatal toxicity cases, YC-backed Origin Bio releases 10,000 AI-generated regulatory elements to program precise expression and reduce off-target effects.

Gene TherapyAi+3

Hero banner illustration for "Digital Twins in Healthcare Hit Inflection Point as Data Race Heats Up"

Healthtech & BiotechMarch 14, 2026

Digital Twins in Healthcare Hit Inflection Point as Data Race Heats Up

As the market for human-in-computer models surges past $3.6B, a new wave of startups like Mantis Biotech are racing to solve the data infrastructure problem holding back adoption.

Digital TwinsHealthtech+3

Hero banner illustration for "Mining Parasite Evolution: YC-Backed Ditto Bio's Autoimmune Gambit"

Healthtech & BiotechMarch 12, 2026

Mining Parasite Evolution: YC-Backed Ditto Bio's Autoimmune Gambit

How a YC W26 biotech is using AI to discover drug candidates from millions of years of parasite-human co-evolution, joining a wave of tolerance-based therapies reshaping autoimmunity.

YcAutoimmune Disease+3

Hero banner illustration for "The AI Race to Make Gene Therapies Safer"

Healthtech & BiotechMarch 12, 2026

The AI Race to Make Gene Therapies Safer

As FDA safety warnings mount, a new wave of AI platforms is redesigning the genetic control switches inside breakthrough therapies—aiming to prevent toxicity before it starts.

Gene TherapyAi+3

Hero banner illustration for "China's BCI Boom: How Brain-Computer Startups Are Racing to Market"

Healthtech & BiotechMarch 12, 2026

China's BCI Boom: How Brain-Computer Startups Are Racing to Market

Record funding, clinical breakthroughs, and sweeping government support are propelling China's brain-computer interface sector from lab to clinic—with implications for global neurotech.

Hero banner illustration for "AI Designs DNA 'Switches' to Make Gene Therapies Safer"

Healthtech & BiotechMarch 11, 2026

AI Designs DNA 'Switches' to Make Gene Therapies Safer

As fatal side effects plague gene therapy, startups like Origin Bio are using machine learning to precisely control where therapeutic genes turn on—addressing a $232B market's safety crisis.

Gene TherapyAi+3

Hero banner illustration for "Mantis Biotech Launches Data Platform for Human Digital Twins"

Healthtech & BiotechMarch 11, 2026

Mantis Biotech Launches Data Platform for Human Digital Twins

YC-backed startup unveils infrastructure to unify fragmented biomedical data as digital twin market races toward $70B by 2035 amid regulatory tailwinds.

YcDigital Twins+3

Hero banner illustration for "How AI Foundation Models Are Solving Biology's Missing Data Problem"

Healthtech & BiotechMarch 6, 2026

How AI Foundation Models Are Solving Biology's Missing Data Problem

YC-backed Strand AI and competitors race to predict unmeasured biological data, promising to accelerate drug discovery in a market projected to reach $13.8B by 2033.

YcAi+2

Hero banner illustration for "How AI Is Solving Biopharma's Hidden Bottleneck in Drug Development"

Healthtech & BiotechMarch 6, 2026

How AI Is Solving Biopharma's Hidden Bottleneck in Drug Development

As AI accelerates drug discovery, protein characterization has become the new rate-limiting step. YC-backed 10x Science aims to compress weeks of analysis into minutes.

YcDrug Development+3

Hero banner illustration for "The Race to Build Digital Humans: Inside Pharma's AI Infrastructure Bet"

Healthtech & BiotechMarch 6, 2026

The Race to Build Digital Humans: Inside Pharma's AI Infrastructure Bet

As regulators greenlight virtual patients and physics-enhanced AI models, startups like Mantis are building the data plumbing for a $70B digital twin revolution in drug development.

AiHealthtech+2

Hero banner illustration for "AI-Designed DNA: The Race to Make Gene Therapies Safer"

Healthtech & BiotechMarch 5, 2026

AI-Designed DNA: The Race to Make Gene Therapies Safer

As safety concerns mount, startups like YC-backed Origin Bio are using AI to engineer regulatory DNA that precisely controls gene expression in CAR-T and AAV therapies.

YcGene Therapy+3

Hero banner illustration for "Mining Parasites for Cures: How Ditto Bio Uses Evolution to Fight Disease"

Healthtech & BiotechMarch 5, 2026

Mining Parasites for Cures: How Ditto Bio Uses Evolution to Fight Disease

YC-backed Ditto Biosciences harnesses millions of years of parasite evolution—analyzing proteins from ticks, worms, and viruses—to develop breakthrough autoimmune therapies.

YcBiotech+2

Hero banner illustration for "Mining Ticks and Worms: Biotech Startup Hunts Autoimmune Drugs in Parasites"

Healthtech & BiotechMarch 5, 2026

Mining Ticks and Worms: Biotech Startup Hunts Autoimmune Drugs in Parasites

YC-backed Ditto Biosciences is using AI to screen millions of parasite proteins for novel autoimmune therapies, betting evolution's immunology tricks can beat traditional antibodies.

YcBiotech+3

Hero banner illustration for "AI Tackles Gene Therapy's Safety Crisis After Fatal FDA Warnings"

Healthtech & BiotechMarch 5, 2026

AI Tackles Gene Therapy's Safety Crisis After Fatal FDA Warnings

Origin.bio's AI platform designs regulatory DNA to prevent toxicity in cell and gene therapies, as industry grapples with liver failure cases and new FDA restrictions.

Gene TherapyArtificial Intelligence+3

Hero banner illustration for "Ditto Bio Mines Parasite Evolution to Design Autoimmune Therapies"

Healthtech & BiotechMarch 4, 2026

Ditto Bio Mines Parasite Evolution to Design Autoimmune Therapies

YC-backed startup uses AI to transform millions of years of parasite immune evasion into novel biologics, screening 1M+ proteins for autoimmune disease targets.

YcBiotech+3

Hero banner illustration for "The Race to Build AI Scientists That Can Run Research Alone"

Healthtech & BiotechMarch 4, 2026

The Race to Build AI Scientists That Can Run Research Alone

YC-backed Synthetic Sciences joins a growing field automating scientific research end-to-end. With benchmarks showing 17-92% accuracy ranges and EU AI rules looming, the stakes are high.

YcAi Agents+3

Hero banner illustration for "Foundation Models Race to Fill Biology's Data Gaps"

Healthtech & BiotechMarch 4, 2026

Foundation Models Race to Fill Biology's Data Gaps

As AI in drug discovery approaches $14B by 2033, startups like YC's Strand AI are building cross-modal models that predict unmeasured biological data—creating virtual assays from routine tests.

YcDrug Discovery+3

Hero banner illustration for "How AI-Designed DNA Is Making Gene Therapies Safer"

Healthtech & BiotechMarch 4, 2026

How AI-Designed DNA Is Making Gene Therapies Safer

As cell and gene therapies expand beyond rare diseases, startups like Origin are using AI to engineer regulatory DNA that controls where and how much therapeutic genes express—tackling a critical safety challenge.

Gene TherapyArtificial Intelligence+2

Hero banner illustration for "How Parasite Proteins Are Becoming Autoimmune Drugs"

Healthtech & BiotechMarch 3, 2026

How Parasite Proteins Are Becoming Autoimmune Drugs

YC-backed Ditto Biosciences mines millions of years of parasite evolution with AI to create next-gen immunotherapies, joining a wave of tolerance-based approaches.

YcBiotech+3

Hero banner illustration for "baCta Raises €7M to Scale Genome-to-Factory AI for Bio-Ingredients"

Healthtech & BiotechMarch 3, 2026

baCta Raises €7M to Scale Genome-to-Factory AI for Bio-Ingredients

French startup's seed round signals autonomous biofoundries are finally reaching commercial scale, promising to transform how industrial ingredients are manufactured.

BiotechArtificial Intelligence+3

Hero banner illustration for "Lab-Grown Neurons Playing DOOM Signal Bio-Computing's Commercial Dawn"

Healthtech & BiotechMarch 2, 2026

Lab-Grown Neurons Playing DOOM Signal Bio-Computing's Commercial Dawn

Cortical Labs' viral demo showcases bioprocessors learning video games—part of an emerging industry tackling AI's energy crisis with living neurons. Inside the $11M startup's tech and rivals.

BiotechAi Hardware+3

Hero banner illustration for "AI Platform Tackles Biotech's $500K-Per-Day Protein Analysis Bottleneck"

Healthtech & BiotechFebruary 28, 2026

AI Platform Tackles Biotech's $500K-Per-Day Protein Analysis Bottleneck

10x Science's AI-native platform automates protein characterization from weeks to minutes, addressing the CMC analytics crisis that derails 74% of FDA drug applications.

Protein CharacterizationBiotech+3

Hero banner illustration for "Digital Twins Are Remaking Drug Development—Here's the Infrastructure Race"

Healthtech & BiotechFebruary 28, 2026

Digital Twins Are Remaking Drug Development—Here's the Infrastructure Race

From virtual hearts to synthetic patients, a new infrastructure layer is emerging to validate human-in-computer models—promising faster trials, safer devices, and personalized medicine.

Digital TwinsDrug Discovery+3

Hero banner illustration for "AI-Designed DNA 'Switches' Promise Safer Gene Therapies"

Healthtech & BiotechFebruary 28, 2026

AI-Designed DNA 'Switches' Promise Safer Gene Therapies

As cell and gene therapies face mounting safety concerns, startups are using AI to precisely control therapeutic gene expression—a potential breakthrough in an $11B+ industry.

Gene TherapyArtificial Intelligence+2

Hero banner illustration for "10x Science Tackles Protein Characterization Bottleneck with AI"

Healthtech & BiotechFebruary 27, 2026

10x Science Tackles Protein Characterization Bottleneck with AI

YC W26 biotech startup aims to close the gap between AI drug discovery and development with automated protein analysis platform, targeting a $40B+ market.

YcProtein Characterization+3

Hero banner illustration for "SHINE Technologies Proves Fusion's Commercial Value Beyond Energy"

Healthtech & BiotechFebruary 27, 2026

SHINE Technologies Proves Fusion's Commercial Value Beyond Energy

Wisconsin-based SHINE has achieved rare commercial success with fusion technology, producing medical isotopes for cancer treatment and operating neutron testing services—years before fusion energy becomes viable.

Nuclear FusionMedical Isotopes+2

Hero banner illustration for "Foundation Models Are Learning to Fill Biology's Data Gaps"

Healthtech & BiotechFebruary 27, 2026

Foundation Models Are Learning to Fill Biology's Data Gaps

AI systems can now predict missing proteins, genes, and spatial data from routine lab tests—unlocking archived patient samples and reshaping drug discovery economics.

Drug DiscoveryArtificial Intelligence+3

Hero banner illustration for "How Powder-Based Drug Delivery Is Reshaping Emergency Medicine"

Healthtech & BiotechFebruary 26, 2026

How Powder-Based Drug Delivery Is Reshaping Emergency Medicine

Orexo's $8M BARDA grant spotlights AmorphOX technology as intranasal powders challenge traditional injections for overdose reversal, anaphylaxis, and beyond.

BiotechDrug Delivery+3

Hero banner illustration for "AI Detects 30% More High-Risk Pregnancies Than Standard Screening"

Healthtech & BiotechFebruary 26, 2026

AI Detects 30% More High-Risk Pregnancies Than Standard Screening

Danish startup Prenaital's deep-learning models address critical gap in prenatal care as ultrasound AI gains FDA clearances and hospital adoption accelerates globally.

Diagnostic ImagingComputer Vision+3

Hero banner illustration for "Ditto Bio Mines Parasites for Autoimmune Drug Discovery Platform"

Healthtech & BiotechFebruary 24, 2026

Ditto Bio Mines Parasites for Autoimmune Drug Discovery Platform

YC-backed startup uses AI to engineer parasite proteins into therapeutics, tapping a $116B+ market with nature-inspired approach validated by founders' Cell publications.

YcDrug Discovery+3

Hero banner illustration for "AI Co-Scientists: How Autonomous Research Agents Are Reshaping Discovery"

Healthtech & BiotechFebruary 23, 2026

AI Co-Scientists: How Autonomous Research Agents Are Reshaping Discovery

From AlphaFold to self-driving labs, AI agents are automating end-to-end scientific workflows. Inside the $18B lab automation revolution transforming drug discovery.

Ai AgentsLab Automation+3

Hero banner illustration for "Mining Millions of Years of Evolution: How Parasites Could Solve Autoimmunity"

Healthtech & BiotechFebruary 23, 2026

Mining Millions of Years of Evolution: How Parasites Could Solve Autoimmunity

Ditto Biosciences is using AI to turn parasite biology into drugs for autoimmune disease—a $271B market where evolution has already done the R&D work.

BiotechDrug Discovery+2

Hero banner illustration for "Programming Precision: AI's Role in Next-Gen Gene Therapy Safety"

Healthtech & BiotechFebruary 22, 2026

Programming Precision: AI's Role in Next-Gen Gene Therapy Safety

As gene therapies face mounting safety concerns, a YC-backed startup and a wave of AI platforms are redesigning the regulatory DNA switches that control therapeutic gene expression.

Gene TherapyArtificial Intelligence+3

Hero banner illustration for "The Rise of Digital Twins: How AI Is Predicting Disease Before Symptoms"

Healthtech & BiotechFebruary 22, 2026

The Rise of Digital Twins: How AI Is Predicting Disease Before Symptoms

From BioTwin to Mayo Clinic, healthcare's digital twin revolution promises to predict diseases years in advance. Inside the technology, market forces, and race to validate AI-powered prevention.

Digital TwinsArtificial Intelligence+3

Hero banner illustration for "The Race to Build Digital Humans: Inside the $15B In-Silico Revolution"

Healthtech & BiotechFebruary 22, 2026

The Race to Build Digital Humans: Inside the $15B In-Silico Revolution

How computational biology startups like Mantis are replacing animal trials with physics-based simulations—and why FDA regulators are finally ready to accept digital evidence.

BiotechDrug Discovery+3

Hero banner illustration for "Strand AI Launches Foundation Models to Fill Gaps in Biological Data"

Healthtech & BiotechFebruary 21, 2026

Strand AI Launches Foundation Models to Fill Gaps in Biological Data

YC-backed startup enters race to build 'foundation models for biology,' promising to predict missing modalities in clinical trials and reduce costly lab assays.

YcBiotech+3

Hero banner illustration for "AI Co-Scientists Take Over Labs in Research Automation Race"

Healthtech & BiotechFebruary 21, 2026

AI Co-Scientists Take Over Labs in Research Automation Race

From drug discovery to materials science, autonomous AI agents are running experiments end-to-end, cutting research cycles from months to days—and billions in funding.

Lab AutomationAi Agents+3

Hero banner illustration for "AI-Designed DNA Could Fix Gene Therapy's Biggest Safety Problem"

Healthtech & BiotechFebruary 21, 2026

AI-Designed DNA Could Fix Gene Therapy's Biggest Safety Problem

As the $25B cell and gene therapy market races toward $100B, Origin.bio's AI platform tackles a critical bottleneck: controlling exactly where and when therapeutic genes turn on.

Gene TherapyArtificial Intelligence+2

Hero banner illustration for "The Race to Build Digital Twins of the Human Body"

Healthtech & BiotechFebruary 21, 2026

The Race to Build Digital Twins of the Human Body

How startups are building infrastructure for human-in-computer models—and why pharma, device makers, and clinical trials are betting billions on physiological simulation.

Digital TwinsSimulation Tech+3

Hero banner illustration for "Mining Parasite Biology for Breakthrough Autoimmune Therapies"

Healthtech & BiotechFebruary 20, 2026

Mining Parasite Biology for Breakthrough Autoimmune Therapies

YC-backed Ditto Biosciences uses AI to screen 1M+ parasite proteins for drug discovery, joining a new wave of startups tapping evolution to treat autoimmune diseases.

YcDrug Discovery+3

Hero banner illustration for "The Race to Build Digital Humans: Inside the $7B In-Silico Trial Boom"

Healthtech & BiotechFebruary 20, 2026

The Race to Build Digital Humans: Inside the $7B In-Silico Trial Boom

How startups like Mantis Biotechnology are creating computational infrastructure to replace animal testing and transform drug development with virtual patients.

Drug DiscoveryClinical Trials+3

Hero banner illustration for "The AI Race to Make Gene Therapies Safer: Inside Regulatory DNA Design"

Healthtech & BiotechFebruary 20, 2026

The AI Race to Make Gene Therapies Safer: Inside Regulatory DNA Design

As gene therapies face mounting safety concerns, a new generation of AI platforms is redesigning the genetic 'control switches' that determine where, when, and how therapeutic genes are expressed.

Gene TherapyArtificial Intelligence+3

Hero banner illustration for "The Race to Build AI Co-Scientists That Can Run Research End-to-End"

Healthtech & BiotechFebruary 19, 2026

The Race to Build AI Co-Scientists That Can Run Research End-to-End

From Google's AI co-scientist to YC's Synthetic Sciences, a new wave of autonomous research platforms promises to transform how drugs are discovered and science gets done.

Ai AgentsDrug Discovery+3

Hero banner illustration for "Inside the Lab Making Whole Bodies Transparent for Precision Medicine"

Healthtech & BiotechFebruary 18, 2026

Inside the Lab Making Whole Bodies Transparent for Precision Medicine

Deep Piction's cellular imaging platform maps drug delivery across entire organisms, tracking single CAR T cells and revealing hidden therapeutic pathways at unprecedented resolution.

Precision MedicineDiagnostic Imaging+3

Hero banner illustration for "Quantum Meets Drug Discovery: Pharmacelera's €6M Bet on Physics-First AI"

Healthtech & BiotechFebruary 18, 2026

Quantum Meets Drug Discovery: Pharmacelera's €6M Bet on Physics-First AI

As AI drug discovery heats up, Barcelona's Pharmacelera raised €6M to bring quantum mechanics-derived models to US pharma—part of a broader shift toward physics-grounded approaches.

Drug DiscoveryQuantum Computing+3

Hero banner illustration for "Mining Parasite Biology: The New Frontier in Autoimmune Drug Discovery"

Healthtech & BiotechFebruary 17, 2026

Mining Parasite Biology: The New Frontier in Autoimmune Drug Discovery

How Ditto Biosciences and a wave of tolerance-focused startups are challenging the $190B autoimmune market with proteins evolved by parasites to control human immunity.

Drug DiscoveryBiotech+2

Hero banner illustration for "How AI-Designed DNA Could Make Gene Therapy Safer"

Healthtech & BiotechFebruary 17, 2026

How AI-Designed DNA Could Make Gene Therapy Safer

YC-backed Origin claims its platform outperforms DeepMind's AlphaGenome in designing regulatory DNA, addressing a $117B+ market plagued by safety setbacks.

Gene TherapyArtificial Intelligence+3

Hero banner illustration for "Cracking Cancer's Code: The Multi-Platform Attack on 'Undruggable' Targets"

Healthtech & BiotechFebruary 17, 2026

Cracking Cancer's Code: The Multi-Platform Attack on 'Undruggable' Targets

How a new generation of biotech companies is finally tackling KRAS, p53, and other once-impossible drug targets using AI, molecular glues, and novel conjugates.

OncologyDrug Discovery+2

Hero banner illustration for "The Race to Build Healthcare's Digital Twin Infrastructure"

Healthtech & BiotechFebruary 16, 2026

The Race to Build Healthcare's Digital Twin Infrastructure

As the healthcare digital twin market surges toward $14B by 2031, infrastructure startups are tackling fragmented data and simulation gaps that cost trials $15M each.

Digital TwinsHealthtech+3

Hero banner illustration for "Mining 1M+ Parasite Proteins: How AI Unlocks Autoimmune Therapies"

Healthtech & BiotechFebruary 15, 2026

Mining 1M+ Parasite Proteins: How AI Unlocks Autoimmune Therapies

YC-backed Ditto Biosciences applies evolutionary biology and AI to discover autoimmune drugs from tick, worm, and viral proteins—targeting a $72B+ market with nature's blueprints.

YcBiotech+3

Hero banner illustration for "AI Drug Discovery's Hidden Bottleneck: Protein Characterization"

Healthtech & BiotechFebruary 15, 2026

AI Drug Discovery's Hidden Bottleneck: Protein Characterization

AlphaFold and AI are flooding pipelines with candidates, but characterization still takes weeks. How next-gen platforms are racing to close the gap.

Drug DiscoveryArtificial Intelligence+3

Healthtech & BiotechFebruary 14, 2026

How AI Foundation Models Are Solving Biology's Missing Data Problem

New multimodal AI models can predict unmeasured biological data from patient datasets, transforming drug discovery and clinical trials. Industry reaches inflection point as startups and Big Pharma race to deploy the technology.

Drug DiscoveryArtificial Intelligence+3

Hero banner illustration for "How AI Is Solving Drug Development's $18B Characterization Problem"

Healthtech & BiotechFebruary 14, 2026

How AI Is Solving Drug Development's $18B Characterization Problem

As AlphaFold accelerates protein discovery, characterization has become biopharma's critical bottleneck. 10x Science's AI platform promises to collapse weeks of analysis into minutes.

Drug DiscoveryArtificial Intelligence+3

Hero banner illustration for "Beyond LNPs: Peptide Carriers Reshape Cancer Drug Delivery Race"

Healthtech & BiotechFebruary 13, 2026

Beyond LNPs: Peptide Carriers Reshape Cancer Drug Delivery Race

As RNA therapies scale to 5,500+ active assets, peptide-based delivery systems from Vectiopep, Sirnaomics, and pHLIP are tackling the endosomal escape barrier blocking cancer treatment success.

BiotechDrug Discovery+2

Hero banner illustration for "AI Co-Scientists: The Race to Automate Scientific Discovery"

Healthtech & BiotechFebruary 13, 2026

AI Co-Scientists: The Race to Automate Scientific Discovery

From Google's multi-agent system to autonomous labs, AI is compressing years of R&D into months—unlocking up to $110B in pharma value while sparking debates over reproducibility.

Ai AgentsDrug Discovery+2

Hero banner illustration for "Mining Parasites for Autoimmune Cures: Ditto's AI-Driven Approach"

Healthtech & BiotechFebruary 12, 2026

Mining Parasites for Autoimmune Cures: Ditto's AI-Driven Approach

YC-backed Ditto Biosciences harnesses millions of years of parasite evolution to discover next-gen autoimmune drugs, using AI to unlock nature's immune evasion toolkit.

YcDrug Discovery+3

Hero banner illustration for "The Rise of AI Co-Scientists: Automating End-to-End Research"

Healthtech & BiotechFebruary 11, 2026

The Rise of AI Co-Scientists: Automating End-to-End Research

How autonomous AI systems are compressing drug discovery from decades to months—and why a new wave of startups is racing to build the infrastructure for AI-powered science.

Drug DiscoveryAi Agents+3

Hero banner illustration for "The Race to Build AI Co-Scientists That Run Research End-to-End"

Healthtech & BiotechFebruary 10, 2026

The Race to Build AI Co-Scientists That Run Research End-to-End

As R&D spend tops $2.8 trillion globally, a new wave of AI infrastructure promises to automate the full research cycle—from hypothesis to lab validation. Can it deliver?

Ai AgentsLab Automation+3

Hero banner illustration for "AI-Designed DNA Controls: The Missing Safety Layer in Gene Therapy"

Healthtech & BiotechFebruary 10, 2026

AI-Designed DNA Controls: The Missing Safety Layer in Gene Therapy

As FDA warnings mount over gene therapy toxicity, startups like Origin are using AI to program precise expression control—addressing the $50B market's biggest risk.

Gene TherapyArtificial Intelligence+3

Hero banner illustration for "How FDA's GLP-1 Crackdown Is Reshaping Telehealth Giants"

Healthtech & BiotechFebruary 9, 2026

How FDA's GLP-1 Crackdown Is Reshaping Telehealth Giants

As FDA ends compounding loopholes, digital health platforms scramble to pivot from $200/month knockoffs to $499 branded drugs—or face DOJ action. Inside the regulatory reckoning.

TelehealthRegulatory Compliance+2

Hero banner illustration for "Omega-3 Research Sparks $2B Market Shift Toward Brain Health"

Healthtech & BiotechFebruary 9, 2026

Omega-3 Research Sparks $2B Market Shift Toward Brain Health

New early-onset dementia study fuels industry pivot to algal sources and biomarker testing, as supplement makers navigate conflicting evidence and regulatory scrutiny.

BiotechLongevity Tech+2

Hero banner illustration for "AI-Designed DNA: The Race to Make Gene Therapy Safer"

Healthtech & BiotechFebruary 8, 2026

AI-Designed DNA: The Race to Make Gene Therapy Safer

As gene therapies face mounting safety concerns, a new wave of startups is using AI to engineer regulatory DNA that could reduce toxicity and unlock precision medicine's promise.

Gene TherapyArtificial Intelligence+3

Hero banner illustration for "The Infrastructure Race Behind In-Silico Medicine's Breakthrough"

Healthtech & BiotechFebruary 8, 2026

The Infrastructure Race Behind In-Silico Medicine's Breakthrough

As FDA and EMA embrace digital twins for drug trials, a new generation of companies is building the data layer that makes human-in-computer models production-ready.

Digital TwinsDrug Discovery+3

Hero banner illustration for "The Infrastructure Race Behind Medicine's Digital Twin Revolution"

Healthtech & BiotechFebruary 7, 2026

The Infrastructure Race Behind Medicine's Digital Twin Revolution

As regulators greenlight virtual human models for drug trials and device testing, a new class of data platforms is emerging to make digital twins production-ready.

Digital TwinsDrug Discovery+3

Hero banner illustration for "Mining Parasites for Autoimmune Cures: Ditto Bio's Evolutionary Bet"

Healthtech & BiotechFebruary 6, 2026

Mining Parasites for Autoimmune Cures: Ditto Bio's Evolutionary Bet

Y Combinator-backed Ditto Biosciences uses AI and parasite genomics to engineer autoimmune therapies, as whole-organism helminth trials falter and the $230B market shifts to tolerance.

YcBiotech+3

Hero banner illustration for "How Digital Twins Are Transforming Drug and Device Development"

Healthtech & BiotechFebruary 6, 2026

How Digital Twins Are Transforming Drug and Device Development

From FDA approvals to $6B market projections, human-in-computer models are moving from research labs to clinical reality—and startups are racing to build the infrastructure.

Digital TwinsDrug Discovery+3

Hero banner illustration for "The Race to Build Digital Humans: Inside the $6B In-Silico Revolution"

Healthtech & BiotechFebruary 6, 2026

The Race to Build Digital Humans: Inside the $6B In-Silico Revolution

As FDA embraces virtual trials and digital twins, a new generation of startups is building the infrastructure to simulate human biology in software—promising to transform drug development.

Digital TwinsDrug Discovery+2

Hero banner illustration for "The Digital Human Revolution: How In-Silico Models Are Replacing Animal Testing"

Healthtech & BiotechFebruary 5, 2026

The Digital Human Revolution: How In-Silico Models Are Replacing Animal Testing

As FDA embraces digital evidence, a $10B market emerges for simulated human biology. Inside the infrastructure layer transforming drug development and medical device testing.

Digital TwinsDrug Discovery+2

Hero banner illustration for "AI Drug Discovery's Hidden Bottleneck: The Protein Problem"

Healthtech & BiotechFebruary 5, 2026

AI Drug Discovery's Hidden Bottleneck: The Protein Problem

YC-backed 10x Science launches platform to solve protein characterization crisis as AI-designed biologics flood development pipelines. Market approaches $66B by 2030.

YcDrug Discovery+3

Hero banner illustration for "Quantum Sensors Enter Biomedicine: QT Sense's €3.6M Breakthrough"

Healthtech & BiotechFebruary 5, 2026

Quantum Sensors Enter Biomedicine: QT Sense's €3.6M Breakthrough

Dutch startup commercializes diamond-based quantum sensing to detect oxidative stress in living cells, opening new frontiers in cancer, fertility, and immune research.

Quantum SensingBiotech+3

Hero banner illustration for "The AI Breakthrough Automating Pharma Lab Quality Checks"

Healthtech & BiotechFebruary 5, 2026

The AI Breakthrough Automating Pharma Lab Quality Checks

Expert Intelligence's Limited Sample Model learns expert judgment from tens of batches, promising 50x faster reviews. Convergence of new regulatory guidance and lab modernization creates opening.

Lab AutomationBiotech+2

Hero banner illustration for "AI Models Learn to Write DNA, Promising Safer Gene Therapies"

Healthtech & BiotechFebruary 5, 2026

AI Models Learn to Write DNA, Promising Safer Gene Therapies

Generative AI is designing regulatory DNA to precisely control gene expression, addressing safety challenges in cell and gene therapies for cancer and brain disorders.

Gene TherapyArtificial Intelligence+2

Hero banner illustration for "Quantum Diamonds Are Coming for Disease Diagnosis"

Healthtech & BiotechFebruary 5, 2026

Quantum Diamonds Are Coming for Disease Diagnosis

How nitrogen-vacancy diamond magnetometry is revolutionizing biomedical diagnostics—from single-cell cancer detection to rapid sepsis screening—and why investors are betting big.

BiotechDiagnostic Imaging+2

Hero banner illustration for "AI Agents Are Running Biology Labs: The Self-Driving Lab Revolution"

Healthtech & BiotechFebruary 5, 2026

AI Agents Are Running Biology Labs: The Self-Driving Lab Revolution

Autonomous AI systems are now planning experiments, writing protocols, and controlling lab robots—accelerating drug discovery 6x faster and reshaping how biotech R&D works.

Artificial IntelligenceBiotech+3

Hero banner illustration for "The Race to Build Infrastructure for Human Digital Twins"

Healthtech & BiotechFebruary 5, 2026

The Race to Build Infrastructure for Human Digital Twins

As regulators embrace computational models and the digital twins market heads toward $60B, startups and giants compete to own the data pipes, simulation engines, and validation frameworks powering precision medicine's future.

Digital TwinsBiotech+3

Hero banner illustration for "Agentic Biology: How AI Agents Are Automating Drug Discovery"

Healthtech & BiotechFebruary 4, 2026

Agentic Biology: How AI Agents Are Automating Drug Discovery

A new wave of AI systems is taking over biological research workflows end-to-end. Meet the startups building autonomous labs that could reshape a $110B opportunity.

Drug DiscoveryArtificial Intelligence+2

Hero banner illustration for "How Compact Brain PET Systems Are Democratizing Dementia Diagnosis"

Healthtech & BiotechFebruary 4, 2026

How Compact Brain PET Systems Are Democratizing Dementia Diagnosis

As new Alzheimer's drugs create surging demand for brain imaging, breakthrough PET technology is bringing trillion-dollar dementia diagnostics out of hospitals and into clinics.

Medical TechBiotech+2

Healthtech & Biotech in Research & Innovation

Saccade builds VR eye test to detect Alzheimer's 15 years early

Autopoiesis Sciences raises $11M to build AI research partner

Autopoiesis Sciences raises $11M to build AI research partner

Halmos Labs automates biotech R&D with AI-driven design

Halmos Labs automates biotech R&D with AI-driven design

Petrichor Bio launches AI wet lab platform for biology

Petrichor Bio launches AI wet lab platform for biology

Aignosis raises ₹4 crore to scale AI autism screening

Aignosis raises ₹4 crore to scale AI autism screening

SuperRadiant builds robotic experimentalists for science

SuperRadiant builds robotic experimentalists for science

Trending Topics

Saccade builds VR eye test to detect Alzheimer's 15 years early

Autopoiesis Sciences raises $11M to build AI research partner

Featured Founders

Want more founders?Step into Founderland

Featured Founders

MORE READS

Saccade builds VR eye test to detect Alzheimer's 15 years early

Autopoiesis Sciences raises $11M to build AI research partner

Halmos Labs automates biotech R&D with AI-driven design

Petrichor Bio launches AI wet lab platform for biology

Aignosis raises ₹4 crore to scale AI autism screening

SuperRadiant builds robotic experimentalists for science

WonderTx builds AI to replace injectable drugs with pills

TareBio develops rapid vaccine platform for cancer, infections

Edgerun launches military exoskeleton with $100M+ in LOIs

WonderTx uses extrapolative AI to turn injections into pills

Parasma trains human brain cells to predict AI tokens

Frontier raises $10M to grow biological brains for AI training

Gamgee raises $4M to scale AI-powered cancer vaccines for dogs

WonderTx builds AI to turn injectable drugs into pills

AI-native radiology practices rebuild care from scratch

Neuromorphic launches plug-and-play robot brains for wet labs

Living Neurons as AI Hardware: Inside the Biocomputing Revolution

The Race to Develop Personalized Vaccines in Weeks, Not Months

The AI Race to Predict Clinical Trial Outcomes Before They Fail

Wetware Computing: How Startups Are Training Brain Cells for AI

The Race to Build Computers from Human Brain Cells

Brain Cells as Processors: Inside Parasma's Biocomputing Breakthrough

The Race to Build Personalized Vaccines in Weeks, Not Months

Living Computers: Inside the Race to Train Brain Cells for AI

MOYA Robot and China's Emotional AI Push Face Verification Hurdles

From Lab Meat to Lipstick: IntegriCulture's Profitable Pivot

How TareBio Aims to Build Personalized Cancer Vaccines in Weeks

Brain Cells as AI Chips: The Race to Build Biological Computers

How AI Radiology Startups Are Bridging India's Healthcare Gap

Atlas Discovery Uses AI to Predict Drug Trial Outcomes

The Probiotic Startup Where Customers Pay to Generate AI Training Data

Living Compute: Startups Train Human Brain Cells to Run AI

Cheiron's $8M Seed Signals Race to Build Operating Systems for Drug R&D

Brain Cells as Computers: Inside the Biotech Race to Power AI

AI Predicting Drug Response: The Race to Fix Clinical Trials

AI Models Predict Drug Response, Promising Faster Clinical Trials

Living Computers: Inside Parasma's Quest to Turn Brain Cells Into AI

AI Models Now Predict Drug Trials—Could Save Billions

Training Brain Cells to Compute: Inside the Biological AI Revolution

OpenAI Researcher Miles Wang Raises $200M for AI Drug Startup at $2B Valuation

Living Neurons as Compute: Inside the Race to Build Biological AI

Brain Cells as Compute: The Biotech Startups Racing to Solve AI's Energy Crisis

Living Neurons as AI Chips: The Race to Build Biological Computers

Living Neurons Meet AI: Inside the Race to Build Biological Computers

How Direct tRNA Charging Measurement Could Fix Biotech's Yield Problem

Brain Cells as AI Compute: Inside the Biocomputing Revolution

Space Becomes the New Drug Lab: Microgravity Testing Goes Commercial

Living Neurons as AI Chips: YC's Bet on Biological Computing

The Race to Build Virtual Cells: AI Models That Predict Drug Response

Virtual Cells: How AI Models Are Reinventing Drug Discovery in 2026

The Virtual Cell Revolution: Mapping Disease Biology With AI

India's First Helium-Free MRI: Can Voxelgrids Crack the Access Gap?

Living Neurons Are Learning to Compute: Inside Biological AI's Race

DNA-Triggered Drugs: Inside the Race to Cure 'Undruggable' Diseases

From Words to Workflows: AI's Push to Automate Lab Instruments

The Race to Reinvent MRI: How Startups Are Making Cancer Screening Affordable

YC-Backed Twolabs Launches Robot Platform to Democratize Caregiving AI

The Race to Program DNA Drugs: Can Biotech Unlock Cancer's 80%?

Space Manufacturing's Bottleneck: The Race to Bring Products Home

The Race to Build Reusable Space Factories: How Reentry Vehicles Are Unlocking Orbital Drug Manufacturing

Foundation Models Come to Drug Manufacturing: AbInitio Bio's Echo

Want more founders?
Step into Founderland